GS-9695 and GS-9822 are subsequent technology Non-Catalytic Website Integrase Inhibitors (NCINIs) with considerably improved efficiency towards HIV in contrast with earlier medication equivalent to BI-224436. Improvement stopped because of vacuolation of the bladder urothelium seen in cynomolgus monkey however not in rat; this lesion was absent in equal preclinical research with BI-224436 (examined in canine and rat).
Lesions had been unlikely to be attributable to focus on since NCINIs particularly goal viral integrase protein and no mammalian homologue is thought. Secondary pharmacology research, mitochondrial toxicity research, immunophenotyping and evaluation of proteins implicated in cell-cell interactions and/or bladder integrity (e-cadherin, pan-cytokeratin, uroplakins) failed to supply any believable rationalization for the species-specificity of the lesion.
Because it was characterised by irritation and disruption of urothelial morphology, we investigated physicochemical adjustments within the bladder of cynomolgus monkey (urinary pH 5.5-7.4) which may not happen within the bladder of rats (urinary pH 7.3-8.5). In measurements of floor exercise, GS-9822 confirmed an uncommon transition from a monolayer to a bilayer on the air/water interface with reducing pH, attributed to the sturdy affiliation between drug molecules in adjoining bilayer leaflets and anticipated to be extremely disruptive to the urothelium.
Structural evaluation of GS-9822 and GS-9695 confirmed zwitterionic traits over the vary of pH anticipated in cynomolgus monkey however not rat urine. This unique floor behaviour is unlikely with BI-224436 since it could transition from impartial to cationic (by no means zwitterionic) with reducing pH. These knowledge present helpful insights to information discovery and growth of NCINIs, associated compounds and zwitterions.
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte damage in metabolic syndrome mannequin rats
Metabolic syndrome (MetS) is related to continual kidney illness and proteinuria. Beforehand, we reported {that a} artificial serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent illness fashions. The current examine evaluated the anti-hypertensive and anti-proteinuric results of CM in MetS mannequin rats (SHR/ND mcr-cp). Rats had been divided into regular salt-fed (NS), excessive salt-fed (HS), HS and CM-treated (CM), and HS and hydralazine-treated (Hyd) teams. Rats had been sacrificed after 4 weeks of remedy. Extreme hypertension and proteinuria had been noticed within the HS group.
Though CM and Hyd equally alleviated hypertension, CM suppressed proteinuria and glomerular sclerosis extra effectively than Hyd. The HS group revealed a lower in podocyte quantity and podocyte-specific molecules, along with a rise in glomerular apoptotic cells and apoptosis-related proteins within the kidney. These adjustments had been considerably attenuated by CM, however not by Hyd.
Moreover, CM ameliorated the apoptotic alerts in murine cultured podocytes stimulated with the excessive glucose and aldosterone medium. In conclusion, CM may exert renoprotective results in MetS mannequin rats, along with the inhibition of podocyte apoptosis. Our examine means that serine protease inhibition might turn into a brand new therapeutic technique towards MetS-related hypertension and renal accidents.
Efficacy and security of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an enlargement cohort of a section I examine
Background osteosarcoma is a uncommon, main malignant bone tumour with restricted out there remedies for superior or recurrent illness, leading to a poor prognosis for sufferers. TAS-115 is a novel tyrosine kinase inhibitor beneath investigation in a section I examine in sufferers with strong tumours. We report knowledge of osteosarcoma sufferers within the enlargement cohort of this ongoing examine.
Sufferers and strategies an evaluation of this multicentre, open-label examine was carried out 6 months after the ultimate affected person was enrolled, and included sufferers aged ≥15 years, with unresectable or recurrent osteosarcoma, and who had refractory to straightforward remedy or for whom no customary remedy was out there. TAS-115 650 mg/day was orally administered in a 5 days on/2 days off schedule.
Outcomes a complete of 20 sufferers with osteosarcoma had been enrolled. The most typical antagonistic drug reactions (ADRs) had been neutrophil depend decreased (75%), aspartate aminotransferase elevated (50%), and platelet depend decreased (50%); 85% of sufferers had grade ≥ Three ADRs. Lengthy-term illness management (>1 yr) with TAS-115 was achieved in three sufferers. One of the best general response was steady illness (50%); no affected person achieved an entire or partial response.
Median progression-free survival was Three months; 4-month and 12-month progression-free charges had been 42% and 31%, respectively. Conclusion the protection and tolerability of TAS-115 and long-term illness stability for sufferers with unresectable or recurrent osteosarcoma had been confirmed on this examine, suggesting that TAS-115 is a promising novel remedy for superior osteosarcoma sufferers. Trial registration quantity: JapicCTI-132333 (registered on November 8, 2013).
Inhibitory neurons within the superior colliculus mediate number of spatially-directed actions
Choice making is a cognitive course of that mediates behaviors essential for survival. Selecting spatial targets is an experimentally-tractable type of resolution making that will depend on the midbrain superior colliculus (SC). Whereas physiological and computational research have uncovered the practical topographic group of the SC, the position of particular SC cell varieties in spatial selection is unknown. Right here, we leveraged conduct, optogenetics, neural recordings and modeling to straight look at the contribution of GABAergic SC neurons to the number of opposing spatial targets.
 Wnt Antagonist, C59 |
|
2063-1 |
Biovision |
|
EUR 164.4 |
Wnt Antagonist, C59 |
|
2063-5 |
Biovision |
|
EUR 430.8 |
 Wnt 6 antibody |
|
20R-1649 |
Fitzgerald |
100 ug |
EUR 807.6 |
|
Description: Rabbit polyclonal Wnt 6 antibody |
 Wnt 2 antibody |
|
20R-1650 |
Fitzgerald |
100 ug |
EUR 807.6 |
|
Description: Rabbit polyclonal Wnt 2 antibody |
 Wnt 4 antibody |
|
20R-1651 |
Fitzgerald |
100 ug |
EUR 807.6 |
|
Description: Rabbit polyclonal Wnt 4 antibody |
 Wnt agonist 1 |
|
B6059-10 |
ApexBio |
10 mg |
EUR 164.4 |
|
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation. |
Wnt agonist 1 |
|
B6059-200 |
ApexBio |
200 mg |
EUR 901.2 |
|
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation. |
Wnt agonist 1 |
|
B6059-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 129.6 |
|
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation. |
Wnt agonist 1 |
|
B6059-50 |
ApexBio |
50 mg |
EUR 428.4 |
|
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation. |
 L Wnt-5a |
|
P0011014 |
Addexbio |
One Frozen vial |
EUR 651.6 |
 Wnt-1 Polyclonal Antibody |
|
ABP52707-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
|
|
Description: A polyclonal antibody for detection of Wnt-1 from Human, Mouse. This Wnt-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Wnt-1 at AA range: 270-350 |
Wnt-1 Polyclonal Antibody |
|
ABP52707-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
|
|
Description: A polyclonal antibody for detection of Wnt-1 from Human, Mouse. This Wnt-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Wnt-1 at AA range: 270-350 |
Wnt-1 Polyclonal Antibody |
|
ABP52707-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
|
|
Description: A polyclonal antibody for detection of Wnt-1 from Human, Mouse. This Wnt-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Wnt-1 at AA range: 270-350 |
 Wnt-16 Polyclonal Antibody |
|
ABP52837-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
|
|
Description: A polyclonal antibody for detection of Wnt-16 from Human, Mouse, Rat. This Wnt-16 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Wnt-16 |
Wnt-16 Polyclonal Antibody |
|
ABP52837-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
|
|
Description: A polyclonal antibody for detection of Wnt-16 from Human, Mouse, Rat. This Wnt-16 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Wnt-16 |
Wnt-16 Polyclonal Antibody |
|
ABP52837-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
|
|
Description: A polyclonal antibody for detection of Wnt-16 from Human, Mouse, Rat. This Wnt-16 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Wnt-16 |
Wnt-1 Polyclonal Antibody |
|
ES3706-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
|
Description: A Rabbit Polyclonal antibody against Wnt-1 from Human/Mouse. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Wnt-1 Polyclonal Antibody |
|
ES3706-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
|
Description: A Rabbit Polyclonal antibody against Wnt-1 from Human/Mouse. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Wnt-16 Polyclonal Antibody |
|
ES3836-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
|
Description: A Rabbit Polyclonal antibody against Wnt-16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
Wnt-16 Polyclonal Antibody |
|
ES3836-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
|
Description: A Rabbit Polyclonal antibody against Wnt-16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
 Wnt-1 Recombinant Protein |
|
40-216-0002mg |
ProSci |
0.002 mg |
EUR 311.1 |
|
Description: Wnt-1 is a secreted protein that signals through the Frizzled family of cell surface receptors and is required for normal embryonic development. Wnt-1 activation induces a complex signaling cascade that ultimately leads to the increased expression of over fifty genes. An important component of Wnt-1 signaling is the stabilization, and resulting accumulation, of the intracellular signaling protein, beta-catenin. Wnt signaling induces and maintains the transformed phenotype and, in certain embryonic cell lines, supports self renewal in the absence of significant differentiation. Elevated levels of Wnt proteins are associated with tumorigenesis and are present in numerous human breast cancers. Mature human Wnt-1 is a glycosylated protein containing 343 amino acid residues. Recombinant human Wnt-1 is a 38.4 kDa, non-glycosylated protein containing 343 amino acid residues. |
Wnt-1 Recombinant Protein |
|
40-216-001mg |
ProSci |
0.01 mg |
EUR 437.1 |
|
Description: Wnt-1 is a secreted protein that signals through the Frizzled family of cell surface receptors and is required for normal embryonic development. Wnt-1 activation induces a complex signaling cascade that ultimately leads to the increased expression of over fifty genes. An important component of Wnt-1 signaling is the stabilization, and resulting accumulation, of the intracellular signaling protein, beta-catenin. Wnt signaling induces and maintains the transformed phenotype and, in certain embryonic cell lines, supports self renewal in the absence of significant differentiation. Elevated levels of Wnt proteins are associated with tumorigenesis and are present in numerous human breast cancers. Mature human Wnt-1 is a glycosylated protein containing 343 amino acid residues. Recombinant human Wnt-1 is a 38.4 kDa, non-glycosylated protein containing 343 amino acid residues. |
 WNT-1, human recombinant |
|
4754-10 |
Biovision |
|
EUR 339.6 |
WNT-1, human recombinant |
|
4754-1000 |
Biovision |
|
EUR 6846 |
WNT-1, human recombinant |
|
4754-50 |
Biovision |
|
EUR 874.8 |
 WNT-7A Recombinant Protein |
|
40-577-0003mg |
ProSci |
0.003 mg |
EUR 311.1 |
|
Description: Wnt-7a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. It is expressed in placenta, kidney, testis, uterus, fetal lung and fetal and adult brain. Most Wnt proteins can signal though a mechanism called the canonical Wnt pathway, in which Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family ultimately leading to the disruption of β-Catenein degradation. Intracellular accumulation of β-Catenin increases translocation of the protein into the nucleus where it binds to TCF/LEF transcription factors and induces the expression of numerous genes. Increased Wnt/β-Catenein signaling is associated with tumorigenesis in a diverse set of human cancers. However, Wnt-7a/Frizzled-9 signaling has been shown to act as a tumor suppressor in non-small cell lung cancers. Recombinant human Wnt-7a is a 35.5 kDa glycoprotein containing 318 amino acids. Due to glycosylation, Wnt-7a migrates between 40-55 kDa by SDS-PAGE gel under unreduced conditions. |
WNT-7A Recombinant Protein |
|
40-577-0015mg |
ProSci |
0.015 mg |
EUR 437.1 |
|
Description: Wnt-7a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. It is expressed in placenta, kidney, testis, uterus, fetal lung and fetal and adult brain. Most Wnt proteins can signal though a mechanism called the canonical Wnt pathway, in which Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family ultimately leading to the disruption of β-Catenein degradation. Intracellular accumulation of β-Catenin increases translocation of the protein into the nucleus where it binds to TCF/LEF transcription factors and induces the expression of numerous genes. Increased Wnt/β-Catenein signaling is associated with tumorigenesis in a diverse set of human cancers. However, Wnt-7a/Frizzled-9 signaling has been shown to act as a tumor suppressor in non-small cell lung cancers. Recombinant human Wnt-7a is a 35.5 kDa glycoprotein containing 318 amino acids. Due to glycosylation, Wnt-7a migrates between 40-55 kDa by SDS-PAGE gel under unreduced conditions. |
 Wnt-9b Recombinant Protein |
|
40-653 |
ProSci |
5 ug |
EUR 311.1 |
|
Description: Formerly known as Wnt-15 or Wnt-14b, Wnt-9b is a secreted glycoprotein belonging to the Wnt family of signaling proteins that are critically involved in maintaining the integrity of both embryonic and adult tissues. Wnt-9b is primarily expressed in adult kidneys and during late embryogenesis, and shares with other Wnt family members the same highly conserved lipid-modified, cysteine-rich domain essential for cell signaling. As is true for most Wnt family members, Wnt-9b functions through the biochemical process known as the canonical Wnt pathway. In this process, Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family, and ultimately results in the disruption of β-catenin degradation. Intracellular accumulation of β-catenin increases translocation of the protein into the nucleus, where it binds to TCF/LEF transcription factors to promote the expression of numerous genes. In this manner, Wnt signaling induces and maintains transformed phenotype, and, in certain embryonic cell lines, supports self-renewal in the absence of significant differentiation. While increased Wnt/β-catenin signaling is associated with tumorigenesis in a diverse set of human cancers, lack of Wnt signaling disrupts transcriptional activation of tumor suppressor genes, and has been shown to result in neoplastic transformation, oncogenesis, and human degenerative diseases. Altered Wnt-9b expression has been shown to result in the underdevelopment of the kidneys, and incomplete lip and cleft fusion in mice. Recombinant Human Wnt-9b is a monomeric glycoprotein containing 335 amino acid residues and has a calculated molecular weight of 36.9 kDa. Due to glycosylation, Recombinant Human Wnt-9b migrates at an apparent molecular weight of approximately 49-54 kDa by SDS-PAGE analysis under non-reducing conditions. |
 WNT-3A Recombinant Protein |
|
40-700 |
ProSci |
2 ug |
EUR 311.1 |
|
Description: Wnt-3a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. Expression of Wnt-3a occurs primarily along the dorsal midline across overlapping regions of the Central Nervous System (CNS). Wnt-3a signaling is essential for various morphogenetic events, including embryonic patterning, cell determination, cell proliferation, CNS development, and cytoskeletal formation. Like other members of this family, Wnt-3a contains a highly conserved lipid-modified, cysteine-rich domain that is essential for cell signaling. During a biochemical process called the canonical Wnt pathway, Wnt family members bind to and activate, seven-pass transmembrane receptors of the Frizzled family, ultimately leading to the disruption of β-catenin degradation. Intracellular accumulation of β-catenin increases translocation of the protein into the nucleus, where it binds to TCF/LEF transcription factors to promote gene expression. Lack of Wnt signaling disrupts transcriptional activation of tumor suppressor genes, and has been shown to result in neoplastic transformation, oncogenesis, and human degenerative diseases. Recombinant Murine Wnt-3a is a monomeric glycoprotein containing 334 amino acid residues. Due to glycosylation, the Murine Wnt-3a migrates at an apparent molecular weight of approximately 38.0-41.0 kDa by SDS-PAGE analysis under non-reducing conditions. |
Wnt-1 Polyclonal Antibody |
|
41535-100ul |
SAB |
100ul |
EUR 302.4 |
Wnt-1 Polyclonal Antibody |
|
41535-50ul |
SAB |
50ul |
EUR 224.4 |
 Wnt 6 Blocking Peptide |
|
33R-10508 |
Fitzgerald |
50 ug |
EUR 418.8 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Wnt 6 antibody, catalog no. 20R-1649 |
 Wnt 2 Blocking Peptide |
|
33R-10509 |
Fitzgerald |
50 ug |
EUR 418.8 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Wnt 2 antibody, catalog no. 20R-1650 |
 Wnt 4 Blocking Peptide |
|
33R-10510 |
Fitzgerald |
50 ug |
EUR 418.8 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Wnt 4 antibody, catalog no. 20R-1651 |
 Wnt-6 Blocking Peptide |
|
3570BP-50 |
Biovision |
|
EUR 183.6 |
 Wnt-1 Blocking Peptide |
|
3571BP-50 |
Biovision |
|
EUR 183.6 |
 Wnt-2 Blocking Peptide |
|
3572RBP-50 |
Biovision |
|
EUR 183.6 |
 Wnt-4 Blocking Peptide |
|
3574BP-50 |
Biovision |
|
EUR 183.6 |
 Protein Wnt-3a Antibody |
|
20-abx110152 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Protein Wnt-3a Antibody |
|
20-abx137444 |
Abbexa |
-
EUR 844.80
-
EUR 393.60
-
EUR 276.00
|
|
|
|
 EZSolution? Wnt Antagonist, C59 |
|
9493-1 |
Biovision |
|
EUR 164.4 |
 Wnt-2, human recombinant |
|
7599-10 |
Biovision |
|
EUR 464.4 |
Wnt-2, human recombinant |
|
7599-1000 |
Biovision |
|
EUR 9585.6 |
Wnt-2, human recombinant |
|
7599-50 |
Biovision |
|
EUR 1423.2 |
 Polyclonal Wnt-6 Antibody |
|
APR00134G |
Leading Biology |
0.1mg |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-6 . This antibody is tested and proven to work in the following applications: |
 Polyclonal Wnt-1 Antibody |
|
APR00135G |
Leading Biology |
0.1mg |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-1 . This antibody is tested and proven to work in the following applications: |
 Polyclonal Wnt-2 Antibody |
|
APR00136G |
Leading Biology |
0.1mg |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-2 . This antibody is tested and proven to work in the following applications: |
 Polyclonal Wnt-4 Antibody |
|
APR00137G |
Leading Biology |
0.1mg |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-4 . This antibody is tested and proven to work in the following applications: |
Polyclonal Wnt-1 Antibody |
|
APR00320G |
Leading Biology |
0.1mg |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-1 . This antibody is tested and proven to work in the following applications: |
Polyclonal Wnt-2 Antibody |
|
APR00346G |
Leading Biology |
0.1ml |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-2 . This antibody is tested and proven to work in the following applications: |
 WNT-3a, Human Recombinant |
|
P1194-100 |
Biovision |
|
EUR 738 |
WNT-3a, Human Recombinant |
|
P1194-20 |
Biovision |
|
EUR 235.2 |
 WNT-7a, Human Recombinant |
|
P1195-100 |
Biovision |
|
EUR 705.6 |
WNT-7a, Human Recombinant |
|
P1195-20 |
Biovision |
|
EUR 222 |
 Wnt-3a GMP, CF |
|
PR15121CF |
Neuromics |
10 ug |
EUR 778.8 |
 L Wnt-3A cells |
|
S0011001 |
Addexbio |
One Frozen vial |
EUR 546 |
 Anti-Wnt-1 antibody |
|
STJ96272 |
St John's Laboratory |
200 µl |
EUR 236.4 |
|
Description: Rabbit polyclonal to Wnt-1. |
 Anti-Wnt-16 antibody |
|
STJ96471 |
St John's Laboratory |
200 µl |
EUR 236.4 |
|
Description: Rabbit polyclonal to Wnt-16. |
Anti-Wnt-1 antibody |
|
STJ98451 |
St John's Laboratory |
100 µl |
EUR 280.8 |
|
Description: Mouse monoclonal to Wnt-1. |
 Anti-Wnt-10b antibody |
|
STJ98452 |
St John's Laboratory |
100 µl |
EUR 280.8 |
|
Description: Mouse monoclonal to Wnt-10b. |
 Anti-Wnt-5a antibody |
|
STJ98453 |
St John's Laboratory |
100 µl |
EUR 280.8 |
|
Description: Mouse monoclonal to Wnt-5a. |
Anti-Wnt-5a antibody |
|
STJ98454 |
St John's Laboratory |
100 µl |
EUR 280.8 |
|
Description: Mouse monoclonal to Wnt-5a. |
) Mouse Protein Wnt-8b (Wnt8b) |
|
1-CSB-EP895748MO |
Cusabio |
-
EUR 733.20
-
EUR 370.80
-
EUR 2192.40
-
EUR 1126.80
-
EUR 1461.60
-
EUR 476.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Mouse Protein Wnt-8b(Wnt8b) expressed in E.coli |
) Human Protein Wnt-3a (WNT3A) |
|
1-CSB-RP155494h |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-3a(WNT3A),partial expressed in E.coli |
) Human Protein Wnt-2 (WNT2) |
|
1-CSB-YP026133HU |
Cusabio |
-
EUR 516.00
-
EUR 280.80
-
EUR 1809.60
-
EUR 770.40
-
EUR 1210.80
-
EUR 349.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-2(WNT2) expressed in Yeast |
) Human Protein Wnt-5a (WNT5A) |
|
1-CSB-YP026138HU |
Cusabio |
-
EUR 516.00
-
EUR 280.80
-
EUR 1809.60
-
EUR 770.40
-
EUR 1210.80
-
EUR 349.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-5a(WNT5A) expressed in Yeast |
) Human Protein Wnt-2b (WNT2B) |
|
1-CSB-YP856613HU |
Cusabio |
-
EUR 703.20
-
EUR 358.80
-
EUR 2606.40
-
EUR 1080.00
-
EUR 1730.40
-
EUR 458.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-2b(WNT2B) expressed in Yeast |
) Human Protein Wnt-10a (WNT10A) |
|
1-CSB-YP884424HU |
Cusabio |
-
EUR 516.00
-
EUR 280.80
-
EUR 1809.60
-
EUR 770.40
-
EUR 1210.80
-
EUR 349.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-10a(WNT10A) expressed in Yeast |
 Wnt-1 Polyclonal Conjugated Antibody |
|
C41535 |
SAB |
100ul |
EUR 476.4 |
) Human Protein Wnt-7b (WNT7B) |
|
1-CSB-BP026142HU |
Cusabio |
-
EUR 1008.00
-
EUR 398.40
-
EUR 2604.00
-
EUR 1362.00
-
EUR 1894.80
-
EUR 564.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-7b(WNT7B) expressed in Baculovirus |
Human Protein Wnt-2b (WNT2B) |
|
1-CSB-CF856613HU |
Cusabio |
-
EUR 1158.00
-
EUR 798.00
-
EUR 858.00
|
|
|
|
|
Description: Recombinant Human Protein Wnt-2b(WNT2B) expressed in in vitro E.coli expression system |
Human Protein Wnt-2 (WNT2) |
|
1-CSB-EP026133HU |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-2(WNT2) expressed in E.coli |
Human Protein Wnt-3a (WNT3A) |
|
1-CSB-EP026136HU |
Cusabio |
-
EUR 524.40
-
EUR 285.60
-
EUR 1852.80
-
EUR 783.60
-
EUR 1234.80
-
EUR 355.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-3a(WNT3A) expressed in E.coli |
) Mouse Protein Wnt-3a (Wnt3a) |
|
1-CSB-EP026136MO |
Cusabio |
-
EUR 524.40
-
EUR 285.60
-
EUR 1852.80
-
EUR 783.60
-
EUR 1234.80
-
EUR 355.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Mouse Protein Wnt-3a(Wnt3a) expressed in E.coli |
) Human Protein Wnt-4 (WNT4) |
|
1-CSB-EP026137HU |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-4(WNT4) expressed in E.coli |
 Human Protein Wnt-5a（WNT5A） |
|
1-CSB-EP026138HU |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-5a（WNT5A） expressed in E.coli |
Human Protein Wnt-5a (WNT5A) |
|
1-CSB-EP026138HUa2 |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-5a(WNT5A) expressed in E.coli |
Human Protein Wnt-5a (WNT5A) |
|
1-CSB-EP026138HUb1 |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-5a(WNT5A) expressed in E.coli |
Human Protein Wnt-5a（WNT5A） |
|
1-CSB-EP026138HUb3 |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-5a（WNT5A） expressed in E.coli |
) Human Protein Wnt-7b (Wnt7b) |
|
1-CSB-EP026142HU |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Protein Wnt-7b(Wnt7b) expressed in E.coli |
) Mouse Protein Wnt-7b (Wnt7b) |
|
1-CSB-EP026142MO |
Cusabio |
-
EUR 524.40
-
EUR 285.60
-
EUR 1852.80
-
EUR 783.60
-
EUR 1234.80
-
EUR 355.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Mouse Protein Wnt-7b(Wnt7b) expressed in E.coli |
 Protein Wnt-3a Polyclonal Antibody |
|
42596-100ul |
SAB |
100ul |
EUR 399.6 |
) Protein Wnt-3a Antibody (HRP) |
|
20-abx108677 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
) Protein Wnt-3a Antibody (Biotin) |
|
20-abx105841 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
) Protein Wnt-3a Antibody (FITC) |
|
20-abx107257 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
 Antibody) Protein Wnt-2 (WNT2) Antibody |
|
abx122394-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
|
 Antibody) Protein Wnt-7b (WNT7B) Antibody |
|
abx122911-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
|
 Antibody) Protein Wnt-5a (Wnt5a) Antibody |
|
20-abx123422 |
Abbexa |
-
EUR 710.40
-
EUR 1028.40
-
EUR 493.20
|
|
|
|
 Antibody) Protein Wnt-6 (WNT6) Antibody |
|
20-abx124423 |
Abbexa |
|
|
|
|
 Antibody) Protein Wnt-3a (WNT3A) Antibody |
|
20-abx136135 |
Abbexa |
-
EUR 594.00
-
EUR 844.80
-
EUR 427.20
|
|
|
|
 Antibody) Protein Wnt-4 (WNT4) Antibody |
|
20-abx142310 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 376.80
|
|
|
|
Protein Wnt-7b (WNT7B) Antibody |
|
20-abx142312 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 376.80
|
|
|
|
Protein Wnt-4 (WNT4) Antibody |
|
20-abx116674 |
Abbexa |
|
|
|
|
 Antibody) Protein Wnt-7a (WNT7A) Antibody |
|
20-abx116675 |
Abbexa |
|
|
|
|
Protein Wnt-3a (WNT3A) Antibody |
|
abx117009-100ug |
Abbexa |
100 ug |
EUR 560.4 |
|
|
Protein Wnt-5a (Wnt5a) Antibody |
|
abx117221-100ug |
Abbexa |
100 ug |
EUR 560.4 |
|
|
Protein Wnt-2 (WNT2) Antibody |
|
20-abx004501 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
Protein Wnt-7b (WNT7B) Antibody |
|
20-abx007049 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
Protein Wnt-4 (WNT4) Antibody |
|
20-abx007069 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
Protein Wnt-3a (WNT3A) Antibody |
|
20-abx000791 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
Protein Wnt-5a (Wnt5a) Antibody |
|
20-abx001745 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
Protein Wnt-7a (WNT7A) Antibody |
|
20-abx004155 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
 Antibody) Protein Wnt-10b (WNT10B) Antibody |
|
abx016022-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
|
 Antibody) Protein Wnt-5a (WNT5A) Antibody |
|
abx016063-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
|
Protein Wnt-5a (WNT5A) Antibody |
|
abx012361-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
|
 Antibody) Protein Wnt-1 (WNT1) Antibody |
|
20-abx008571 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
Protein Wnt-10b (WNT10B) Antibody |
|
abx032891-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Protein Wnt-10b (WNT10B) Antibody |
|
abx032891-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Protein Wnt-4 (WNT4) Antibody |
|
abx032933-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Protein Wnt-4 (WNT4) Antibody |
|
abx032933-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Protein Wnt-4 (WNT4) Antibody |
|
abx032934-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Protein Wnt-4 (WNT4) Antibody |
|
abx032934-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Protein Wnt-6 (WNT6) Antibody |
|
abx028898-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Protein Wnt-6 (WNT6) Antibody |
|
abx028898-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Though GABAergic SC neurons comprise a heterogeneous inhabitants with native and long-range projections, our outcomes display that GABAergic SC neurons don’t regionally suppress premotor output, suggesting that practical long-range inhibition as an alternative performs a dominant position in spatial selection. An attractor mannequin requiring solely intrinsic SC circuitry was adequate to account for our experimental observations. General, our examine elucidates the position of GABAergic SC neurons in spatial selection.
